Everything we've seen

1. ·Jun 29, 2:15 PMstreamnews

   Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic

   Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.

2. ·Jun 29, 2:15 PMstreamnews

   Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says

   Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership

3. ❖Jun 29, 12:29 PMnewsvia finnhub

   Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says

   Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership

4. ✓Jun 29, 9:51 AMdecisionacted

   Agent 6 — Options Momentum — decide: buy

   CALL on EW — 5-day return 7.11% with close above 20-day MA ($87.47). IV 25.8%. Sized 1 contract(s) at $2.97 premium.

5. ❖Jun 29, 7:16 AMnewsvia finnhub

   Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic

   Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.

6. ?Jun 22, 3:40 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   With only 5 minutes remaining until the forced close cutoff, there is virtually no time for continuation to materialize into a meaningful position. The -2.08% move is real and represents genuine flow, but at this point in the session the risk/reward of chasing is poor — even a legitimate continuation setup can't develop in 5 minutes. The macro context (T5YIE below trend) is mildly supportive of risk-off sentiment but is not sector-specific to EW (medical devices/cardiac). No headlines to anchor the move. With the EOD flatten at 3:45 PM ET imminent, mean-reversion or position squaring is more likely than fresh continuation selling. Probability set below 0.5 solely due to the extreme time constraint — this is a time-decay disqualifier, not a signal disqualifier.

7. !Jun 22, 3:40 PMsignalseverity -0.02

   Agent 7 — Day Trader — day_trade_skipped

   With only 5 minutes remaining until the forced close cutoff, there is virtually no time for continuation to materialize into a meaningful position. The -2.08% move is real and represents genuine flow, but at this point in the session the risk/reward of chasing is poor — even a legitimate continuation setup can't develop in 5 minutes. The macro context (T5YIE below trend) is mildly supportive of risk-off sentiment but is not sector-specific to EW (medical devices/cardiac). No headlines to anchor the move. With the EOD flatten at 3:45 PM ET imminent, mean-reversion or position squaring is more likely than fresh continuation selling. Probability set below 0.5 solely due to the extreme time constraint — this is a time-decay disqualifier, not a signal disqualifier.

8. ?Jun 16, 9:35 AMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   EW is up 1.64% intraday, a modest but real move suggesting some buying interest. No headlines are driving the move, which means it's likely flow/technical rather than event-driven — not a disqualifier per framework. Macro context shows T10Y2Y at 2.1σ below trend (flattening/near-inversion), which favors defensives, and EW (Edwards Lifesciences, a medical devices/cardiac company) falls broadly in the healthcare/defensive space, providing mild tailwind alignment. However, the move is below the 2% threshold for 'highly meaningful' conviction, and with 370 minutes remaining (essentially a full session ahead), there's plenty of time for both continuation and reversal. No strong reversal signal or fade pattern is evident. On balance, lean slight continuation but with low conviction — assigning just above the 0.5 cutoff given the defensive sector support and absence of counter-catalysts.

9. !Jun 16, 9:35 AMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   EW is up 1.64% intraday, a modest but real move suggesting some buying interest. No headlines are driving the move, which means it's likely flow/technical rather than event-driven — not a disqualifier per framework. Macro context shows T10Y2Y at 2.1σ below trend (flattening/near-inversion), which favors defensives, and EW (Edwards Lifesciences, a medical devices/cardiac company) falls broadly in the healthcare/defensive space, providing mild tailwind alignment. However, the move is below the 2% threshold for 'highly meaningful' conviction, and with 370 minutes remaining (essentially a full session ahead), there's plenty of time for both continuation and reversal. No strong reversal signal or fade pattern is evident. On balance, lean slight continuation but with low conviction — assigning just above the 0.5 cutoff given the defensive sector support and absence of counter-catalysts.

10. ?Jun 12, 11:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down 1.57% today, a modest but real move suggesting some selling pressure. There are no headlines to explain the move, which means it could be sector rotation, quiet institutional distribution, or sympathy flow. EW (Edwards Lifesciences) is a medical device/healthcare name — defensive in character — which is mildly interesting given the macro context: T10Y2Y at 0.4 and 2.1σ below trend suggests a flattening curve environment that historically favors defensives. This is a mild tailwind for EW's sector, which slightly argues against continuation of the downside. However, the move is not large enough to signal panic selling or a clear breakdown, and with 285 minutes remaining there is ample time for the move to extend if selling pressure persists. The absence of news cuts both ways — no catalyst to drive a sharp reversal, but also no identifiable driver to sustain the selloff into the close. The defensive sector backdrop provides a modest counterargument to continuation. On balance, this is a borderline read: momentum is modestly negative, time is ample, but macro sector context mildly opposes the move. Probability sits at the threshold — taking the trade per system rules given bounded downside risk.

11. !Jun 12, 11:00 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is down 1.57% today, a modest but real move suggesting some selling pressure. There are no headlines to explain the move, which means it could be sector rotation, quiet institutional distribution, or sympathy flow. EW (Edwards Lifesciences) is a medical device/healthcare name — defensive in character — which is mildly interesting given the macro context: T10Y2Y at 0.4 and 2.1σ below trend suggests a flattening curve environment that historically favors defensives. This is a mild tailwind for EW's sector, which slightly argues against continuation of the downside. However, the move is not large enough to signal panic selling or a clear breakdown, and with 285 minutes remaining there is ample time for the move to extend if selling pressure persists. The absence of news cuts both ways — no catalyst to drive a sharp reversal, but also no identifiable driver to sustain the selloff into the close. The defensive sector backdrop provides a modest counterargument to continuation. On balance, this is a borderline read: momentum is modestly negative, time is ample, but macro sector context mildly opposes the move. Probability sits at the threshold — taking the trade per system rules given bounded downside risk.

12. ?Jun 12, 9:50 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down 1.66% intraday — a modest but real move that suggests some selling pressure. However, several factors limit conviction: (1) No news catalyst identified, so the move lacks a clear narrative driver that would sustain momentum. (2) The macro context (T10Y2Y at 2.1σ below trend, favoring defensives in bear-flattening) is mildly supportive of defensive names like EW (medtech/cardiac devices), which could attract rotation buying into the close rather than further selling. (3) The move magnitude of ~1.66% is meaningful but not outsized — not the kind of 3-5% flush that typically signals strong institutional distribution. (4) With 355 minutes remaining (nearly full session still ahead), there is ample time for either continuation or reversal. Balancing the real but modest downside momentum against a macro backdrop that is not hostile to defensives and the absence of a news-driven catalyst, this sits at the borderline. Assigning exactly 0.5 — the move is real enough to not fade outright, but no strong reason to chase it lower aggressively.

13. !Jun 12, 9:50 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is down 1.66% intraday — a modest but real move that suggests some selling pressure. However, several factors limit conviction: (1) No news catalyst identified, so the move lacks a clear narrative driver that would sustain momentum. (2) The macro context (T10Y2Y at 2.1σ below trend, favoring defensives in bear-flattening) is mildly supportive of defensive names like EW (medtech/cardiac devices), which could attract rotation buying into the close rather than further selling. (3) The move magnitude of ~1.66% is meaningful but not outsized — not the kind of 3-5% flush that typically signals strong institutional distribution. (4) With 355 minutes remaining (nearly full session still ahead), there is ample time for either continuation or reversal. Balancing the real but modest downside momentum against a macro backdrop that is not hostile to defensives and the absence of a news-driven catalyst, this sits at the borderline. Assigning exactly 0.5 — the move is real enough to not fade outright, but no strong reason to chase it lower aggressively.

14. ?Jun 5, 9:45 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up ~1.91% intraday with 360 minutes remaining (essentially a full session still ahead), suggesting this is a relatively early-stage move with room to develop. No catalyst headline is present, but per guidance, absence of news does not disqualify momentum — real flow with size likely drove this. EW is a medical device/cardiac care company (Edwards Lifesciences), which falls broadly in the defensives/healthcare space. The macro context shows T10Y2Y at 0.42, about 1.9σ below the 24-month trend, reflecting a flattening/slightly inverted curve environment. This macro setup is cited as supportive for defensives (bear-flattening), which could provide a mild tailwind for EW as a defensive healthcare name. There is no reversal signal noted, no thin-volume flag, and ample time remains. The move is below the 2-5% 'high conviction' threshold, keeping this in the ordinary momentum bucket. Overall, modest continuation bias with no strong reason to fade — probability sits at the low end of the continuation range.

15. !Jun 5, 9:45 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is up ~1.91% intraday with 360 minutes remaining (essentially a full session still ahead), suggesting this is a relatively early-stage move with room to develop. No catalyst headline is present, but per guidance, absence of news does not disqualify momentum — real flow with size likely drove this. EW is a medical device/cardiac care company (Edwards Lifesciences), which falls broadly in the defensives/healthcare space. The macro context shows T10Y2Y at 0.42, about 1.9σ below the 24-month trend, reflecting a flattening/slightly inverted curve environment. This macro setup is cited as supportive for defensives (bear-flattening), which could provide a mild tailwind for EW as a defensive healthcare name. There is no reversal signal noted, no thin-volume flag, and ample time remains. The move is below the 2-5% 'high conviction' threshold, keeping this in the ordinary momentum bucket. Overall, modest continuation bias with no strong reason to fade — probability sits at the low end of the continuation range.

16. ?Jun 3, 1:01 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down 1.56% intraday with no catalytic headlines to explain the move. At this magnitude (~1.5%), the move is on the lower end of meaningful conviction signals — real but not emphatic. The macro context (T10Y2Y at 2.1σ below trend, a compressed/flat yield curve environment) is modestly supportive of defensives like EW (cardiovascular medical devices), which could limit further downside or even attract rotation-based buying into the close. However, there is no explicit positive catalyst to reverse the move either. With 165 minutes remaining — a meaningful portion of the session — there is adequate time for continuation if sellers retain control. Balancing: (1) modest-magnitude move with unclear catalyst suggests possible fade, (2) flat/flattening yield curve is not a headwind for EW specifically, (3) absence of news is neutral by design, (4) time remaining is sufficient for further directional movement. On net, this is a borderline read with no strong reason to expect reversal but also no clear continuation pressure. Assigning the minimum threshold probability consistent with the system's bias toward action on ambiguous setups.

17. !Jun 3, 1:01 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is down 1.56% intraday with no catalytic headlines to explain the move. At this magnitude (~1.5%), the move is on the lower end of meaningful conviction signals — real but not emphatic. The macro context (T10Y2Y at 2.1σ below trend, a compressed/flat yield curve environment) is modestly supportive of defensives like EW (cardiovascular medical devices), which could limit further downside or even attract rotation-based buying into the close. However, there is no explicit positive catalyst to reverse the move either. With 165 minutes remaining — a meaningful portion of the session — there is adequate time for continuation if sellers retain control. Balancing: (1) modest-magnitude move with unclear catalyst suggests possible fade, (2) flat/flattening yield curve is not a headwind for EW specifically, (3) absence of news is neutral by design, (4) time remaining is sufficient for further directional movement. On net, this is a borderline read with no strong reason to expect reversal but also no clear continuation pressure. Assigning the minimum threshold probability consistent with the system's bias toward action on ambiguous setups.

18. ❖May 28, 11:30 AMnewsvia finnhub

    OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?

    OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

19. ❖May 28, 8:59 AMnewsvia finnhub

    Josh Brown's 'best stocks in the market': Edwards Lifesciences

    Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail Ritholt's new "Porterhouse" strategy. Josh also spotlights Edwards Lifesciences in his "Best Stocks in the Market."

20. ❖May 27, 10:04 PMnewsvia finnhub

    Is Edwards Lifesciences (EW) Fairly Priced After Recent Share Price Strength?

    Wondering if Edwards Lifesciences at around US$86.51 is offering good value today, or if the recent share price leaves little margin for error. The stock has returned 4.3% over the last week, 3.7% over the past month, 1.4% year to date, and 12.8% over the past year, while the 3 year return sits at 2.7% and the 5 year return shows a decline of 7.4%. Recent coverage has focused on Edwards Lifesciences as a key player in medical equipment, with attention on how its products fit into long term...

21. ▣May 27, 8:00 PMjournalstop

    Agent 6 — Options Momentum closed long 200 @ $2.96 (-$42.38)

    Stop: premium $2.96 ≤ trailing floor $2.98 (peak $3.98 × 0.75)

22. ?May 27, 9:10 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 2.05% intraday with no headline catalyst, suggesting this is flow/technical driven rather than news-driven — which can mean either institutional accumulation or a fade setup. The macro context shows T10Y3M at 1.9σ above trend, which is mildly risk-positive (steepening yield curve) but primarily relevant to banks/recession-sensitive sectors, not directly to EW (Edwards Lifesciences, a medical devices name). With 395 minutes remaining (well over 6 hours, though market closes at 4 PM so this likely means ~75 minutes of trading left), there is reasonable time for continuation. However, the absence of news and the moderate move size (not a breakout gap on catalyst) suggest conviction is unclear. No reversal signals are visible, and the default lean per system rules favors continuation given no strong fade reason. Assigning a modest continuation probability above 0.5 reflecting ordinary momentum with no specific tailwind or headwind.

23. !May 27, 9:10 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 2.05% intraday with no headline catalyst, suggesting this is flow/technical driven rather than news-driven — which can mean either institutional accumulation or a fade setup. The macro context shows T10Y3M at 1.9σ above trend, which is mildly risk-positive (steepening yield curve) but primarily relevant to banks/recession-sensitive sectors, not directly to EW (Edwards Lifesciences, a medical devices name). With 395 minutes remaining (well over 6 hours, though market closes at 4 PM so this likely means ~75 minutes of trading left), there is reasonable time for continuation. However, the absence of news and the moderate move size (not a breakout gap on catalyst) suggest conviction is unclear. No reversal signals are visible, and the default lean per system rules favors continuation given no strong fade reason. Assigning a modest continuation probability above 0.5 reflecting ordinary momentum with no specific tailwind or headwind.

24. ❖May 27, 6:32 AMnewsvia finnhub

    Edwards Lifesciences Has Everything Investors Want Except Value

    Edwards Lifesciences remains a high-quality business with a wide economic moat , but the stock is still overvalued. Click here to read more on the EW stock.

25. ❖May 26, 9:52 AMnewsvia finnhub

    Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth

    WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.

26. ?May 26, 9:31 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 3.10% intraday with no attributable headline, suggesting real institutional flow driving the move. As a medical device / cardiac valve company, EW is a defensive-leaning healthcare name that is relatively insulated from the macro context flagged (T10Y2Y at 0.43, below trend — primarily relevant to banks and broader defensives, not directly negative for med-tech). With 375 minutes remaining (roughly 6+ hours, well into the trading day), there is ample time for continuation but also for mean-reversion. The absence of a catalyst is neutral per guidance. The move is at the lower bound of the 'meaningful conviction' range (3.1%), not a blowout gap. No reversal signals or volume concerns are specifically noted, but the lack of a clear catalyst and the already-extended intraday gain suggest limited additional upside pressure rather than strong continuation. Probability is modestly above 0.5 — sufficient to take a position per system rules, but not a high-conviction setup warranting 0.7+.

27. !May 26, 9:31 AMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 3.10% intraday with no attributable headline, suggesting real institutional flow driving the move. As a medical device / cardiac valve company, EW is a defensive-leaning healthcare name that is relatively insulated from the macro context flagged (T10Y2Y at 0.43, below trend — primarily relevant to banks and broader defensives, not directly negative for med-tech). With 375 minutes remaining (roughly 6+ hours, well into the trading day), there is ample time for continuation but also for mean-reversion. The absence of a catalyst is neutral per guidance. The move is at the lower bound of the 'meaningful conviction' range (3.1%), not a blowout gap. No reversal signals or volume concerns are specifically noted, but the lack of a clear catalyst and the already-extended intraday gain suggest limited additional upside pressure rather than strong continuation. Probability is modestly above 0.5 — sufficient to take a position per system rules, but not a high-conviction setup warranting 0.7+.

28. ✓May 22, 6:00 PMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    CALL on EW — 5-day return 5.39% with close above 20-day MA ($82.21). IV 29.3%. Sized 2 contract(s) at $3.17 premium.

29. ?May 22, 2:41 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 2.84% intraday with no attributable headline, suggesting institutional flow or sector rotation driving the move. The macro context shows T10Y3M at 0.89, elevated above trend — this is modestly supportive of risk-on positioning but primarily flags Banks and recession-sensitive sectors, not medical devices/healthcare where EW operates, so macro is largely neutral here. With 64 minutes remaining there is some runway but not abundant time for a full continuation leg. No reversal signal is apparent, but the absence of a catalyst and limited time compress the probability. Baseline momentum favors continuation slightly; no strong reason to fade.

30. !May 22, 2:41 PMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 2.84% intraday with no attributable headline, suggesting institutional flow or sector rotation driving the move. The macro context shows T10Y3M at 0.89, elevated above trend — this is modestly supportive of risk-on positioning but primarily flags Banks and recession-sensitive sectors, not medical devices/healthcare where EW operates, so macro is largely neutral here. With 64 minutes remaining there is some runway but not abundant time for a full continuation leg. No reversal signal is apparent, but the absence of a catalyst and limited time compress the probability. Baseline momentum favors continuation slightly; no strong reason to fade.

31. ?May 22, 11:45 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 1.82% intraday — a meaningful but not extreme move. No catalyst headlines are available, so this appears to be flow-driven. The macro context (T10Y3M at 2.2σ above trend) is modestly supportive of risk-on positioning but primarily affects banks and recession-sensitive sectors rather than medtech/cardiac devices like EW. With 240 minutes remaining there is ample time for continuation, which is a positive. However, the absence of a clear catalyst and the moderate magnitude of the move (not yet in the 2-5% 'high conviction' zone) limit confidence. No reversal signals are evident. Overall, this is a mild momentum continuation setup with no strong reason to expect a fade, warranting a modest probability above 0.5.

32. !May 22, 11:45 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 1.82% intraday — a meaningful but not extreme move. No catalyst headlines are available, so this appears to be flow-driven. The macro context (T10Y3M at 2.2σ above trend) is modestly supportive of risk-on positioning but primarily affects banks and recession-sensitive sectors rather than medtech/cardiac devices like EW. With 240 minutes remaining there is ample time for continuation, which is a positive. However, the absence of a clear catalyst and the moderate magnitude of the move (not yet in the 2-5% 'high conviction' zone) limit confidence. No reversal signals are evident. Overall, this is a mild momentum continuation setup with no strong reason to expect a fade, warranting a modest probability above 0.5.

33. ▢May 21, 8:00 PMjournal

    Agent 6 — Options Momentum opened long 200 @ $3.17

34. ✓May 19, 7:01 AMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    CALL on EW — 5-day return 6.76% with close above 20-day MA ($81.76). IV 36.1%. Sized 2 contract(s) at $3.81 premium.